Overview

* Regenxbio ( RGNX ) Q3 revenue rises to $29.7 mln from $24.2 mln year-over-year

* Net loss for Q3 widens to $61.9 mln from $59.6 mln year-over-year

* Regenxbio's ( RGNX ) cash position improves to $302 mln, funding operations into early 2027

Outlook

* Regenxbio ( RGNX ) expects cash to fund operations into early 2027

Result Drivers

* Research and development expenses were $56.1 million for the three months ended September 30, 2025, compared to $54.4 million for the three months ended September 30, 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $23.61

License mln

&

Royalty

Revenue

Q3 Net -$61.94

Income mln

Q3 $82.14

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Regenxbio Inc ( RGNX ) is $34.00, about 65.9% above its November 5 closing price of $11.61

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)